| http://www.w3.org/ns/prov#value | - At the April annual meeting of the Food and Drug Law Institute (FDLI), FDA Commissioner Margaret Hamburg voiced support for legislative language that would provide clarity to industry and the public on the use of accelerated approval for a wide variety of diseases and conditions, including rare diseases.
|
